[1]褚宇鹏,孙妲男,李勇,等.解毒活血汤对CKD大鼠肾脏保护作用及对TGF-β1、α-SMA蛋白表达的影响[J].陕西中医,2025,46(12):1610-1615.[doi:DOI:10.3969/j.issn.1000-7369.2025.12.005]
　CHU Yupeng,SUN Danan,LI Yong,et al.Protective effect of Jiedu Huoxue decoction on the kidney of CKD rats and impact on TGF-β1 and α-SMA protein expression[J].,2025,46(12):1610-1615.[doi:DOI:10.3969/j.issn.1000-7369.2025.12.005]
点击复制

解毒活血汤对CKD大鼠肾脏保护作用及对TGF-β1、α-SMA蛋白表达的影响

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年12期
页码:
1610-1615
栏目:
基础研究
出版日期:
2025-12-05

文章信息/Info

Title:
Protective effect of Jiedu Huoxue decoction on the kidney of CKD rats and impact on TGF-β1 and α-SMA protein expression
作者:
褚宇鹏1; 孙妲男2; 李勇2; 徐丽2; 周鹏1; 侯兴1; 杨灡1; 代璇1; 李敬槟1
（1.黑龙江中医药大学研究生院，黑龙江 哈尔滨 150040；2.黑龙江中医药大学附属第二医院肾内科，黑龙江 哈尔滨 150001）
Author(s):
CHU Yupeng1; SUN Danan2; LI Yong2; XU Li2; ZHOU Peng1; HOU Xing1; YANG Lan1; DAI Xuan1; LI Jingbin1
(1.Graduate School of Heilongjiang University of Traditional Chinese Medicine,Harbin 150040,China；2.Department of Nephrology,Affiliated Second Hospital of Heilongjiang University of Chinese Medicine，Harbin 150001，China)
关键词:
慢性肾脏病; 解毒活血汤; 细胞外基质; 转化生长因子-β1; α-平滑肌肌动蛋白; Western-blot
Keywords:
Chronic kidney disease; Jiedu Huoxue decoction; Extracellular matrix; TGF-β1; α-SMA; Western-blot
分类号:
R 692
DOI:
DOI:10.3969/j.issn.1000-7369.2025.12.005
文献标志码:
A
摘要:
目的：探讨解毒活血汤对慢性肾脏病(CKD)大鼠肾功能、转化生长因子-β1（TGF-β1）、α-平滑肌肌动蛋白（α-SMA）的影响。方法：选取7周龄SPF级雄性SD大鼠72只，随机分为空白组、模型组、高剂量组（解毒活血汤煎剂，3.16 g/kg）、中剂量组（解毒活血汤煎剂，1.58 g/kg）、低剂量组（解毒活血汤煎剂，0.79 g/kg）、阳性对照组（尿毒清颗粒，1.81 g/kg），每组各12只。采用5/6肾切除方法制作CKD大鼠模型。各组造模8周后开始药物灌胃，共12周。各组大鼠于药物灌胃4周末采血，并检测肾功能相关指标，12周后采用Western-blot法检测TGF-β1、α-SMA蛋白表达，并用SPSS 26.0统计软件进行数据处理。 结果：与空白组比较，其余各组大鼠血清钙、磷、尿素氮、肌酐和TGF-β1、α-SMA蛋白表达均有显著差异（P＜0.05或P＜0.01）。相较于模型组，各剂量组血清磷、尿素氮、肌酐均明显降低（P＜0.05），血钙明显升高（P＜0.05），TGF-β1、α-SMA蛋白表达明显降低（P＜0.05或P＜0.01）。与低剂量组相比，中、高剂量组TGF-β1、α-SMA蛋白表达明显下降（P＜0.05）；与高剂量组相比，中、低剂量组TGF-β1、α-SMA蛋白表达明显升高（P＜0.05）。结论：解毒活血汤的治疗效果伴随TGF-β1、α-SMA蛋白表达下调，提示其作用可能与抑制纤维化通路相关。
Abstract:
Objective:To investigate the effects of Jiedu Huoxue decoction on renal function,Transforming Growth Factor-β1 (TGF-β1),and α-Smooth Muscle Actin (α-SMA) in rats with chronic kidney disease (CKD).Methods:Seventy-two 7-week-old male SD rats of SPF grade were randomly divided into six groups (n=12 per group):Control group,Model group,High-dose Jiedu Huoxue decoction group (3.16 g/kg),Medium-dose Jiedu Huoxue decoction group (1.58 g/kg),Low-dose Jiedu Huoxue decoction group (0.79 g/kg),and Positive control group (Niaoduqing granule,1.81 g/kg).A CKD rat model was established using the 5/6 nephrectomy method.Drug administration via intragastric gavage began 8 weeks after modeling and lasted for 12 weeks.Blood was collected from all groups at the end of the 4th week of gavage for renal function parameter testing.After 12 weeks,TGF-β1 and α-SMA protein expression levels were detected using Western blot.Data were processed using SPSS 26.0 statistical software.Results:Compared with the Control group,serum calcium,phosphorus,urea nitrogen,creatinine,and TGF-β1 and α-SMA protein expression levels showed significant differences in all other groups (P<0.05 or P<0.01).Compared with the Model group,all Jiedu Huoxue decoction treatment groups exhibited significantly lower serum phosphorus,urea nitrogen,and creatinine (P<0.05),significantly higher serum calcium (P<0.05),and significantly reduced TGF-β1 and α-SMA protein expression (P<0.05 or P<0.01).Compared with the Low-dose group,the Medium-dose and High-dose groups showed significantly lower TGF-β1 and α-SMA protein expression (P<0.05).Compared to the High-dose group,the Low-dose and Medium-dose groups showed significantly higher TGF-β1 and α-SMA protein expression (P<0.05).Conclusion:The therapeutic effect of Jiedu Huoxue decoction was accompanied by downregulation of TGF-β1 and α-SMA protein expression,suggesting its action may be related to the suppression of the fibrotic pathway.

参考文献/References:

[1]TOYODA K,NINOMIYA T.Stroke and cerebrovascular diseases in patients with chronic kidney disease[J].Lancet Neurol，2014，13(8):823-833.
[2]RUIZ-ORTEGA M,RAYEGO-MATEOS S,LAMAS S,et al.Targeting the progression of chronic kidney disease[J].Nat Rev Nephrol,2020,16(5):269-288.
[3]ZHANG L,WANG F,WANG L,et al.Prevalence of chronic kidney disease in China:Across-sectional survey[J].Lancet,2012,379(9818):820-822.
[4]朱思懿,洪航,边学燕,等.慢性肾脏病流行病学研究进展[J].预防医学,2023,35(9):770-773.
[5]MICHAEL Z,ERIC G N.Mechanisms of tubulointerstitial fibrosis[J].Journal of the American Society of Nephrology:JASN,2010,21(11):1819-1834.
[6]GIFFORD C C,TANG J,COSTELLO A,et al.Negative regulators of TGF-β1 signaling in renal fibrosis:Pathological mechanisms and novel therapeutic opportunities[J].Clin Sci(Lond),2021,135(2):275-303.
[7]孔明慧,袁洋,党艳梅.转化生长因子-β1/Smad信号通路对肾纤维化调控机制的研究进展[J].中国临床实用医学，2020，11（5）:78-80.
[8]SHAN G,ZHOU X J,XIA Y,et al.Astragalus membranaceus ameliorates renal interstitial fibrosis by inhibiting tubular epithelial-mesenchymal transition in vivo and in vitro[J].Exp Ther Med，2016，11(5):1611-1616.
[9]HU M C，KURO O M，MOE O W.Renal and extrarenal actions of Klotho[J].Seminars in Nephrology，2013，33:118-129.
[10]史本康,李永智,张建平,等.羟脯氨酸、转化生长因子β1和碱性成纤维细胞生长因子在糖尿病大鼠膀胱纤维化中的作用[J].中华外科杂志，2008，46(8):625-626.
[11]贾会玉,李中南,陈光亮.转化生长因子-β1 介导的 Smads 和MAPKs 信号通路在糖尿病肾病中的作用及其抑制剂研究进展[J].中国临床药理学与治疗学，2015，20(10):1171-1176.
[12]常巨平,祝胜郎,余学清,等.ERK1/2信号蛋白在糖尿病小鼠肾组织中的表达[J].中国病理生理杂志，2007，23(9):1804-1807.
[13]HE Y，ZENG H，YU Y，et al.Resveratrol improved detrusor fibrosis induced by mast cells during progression of chronic prostatitis in rats[J].Eur J Pharmacol，2017，815:495-500.
[14]陈茜楠,王自敏,邢海燕.王自敏基于“虚、浊、瘀、毒”治疗慢性肾衰竭经验[J].长春中医药大学学报，2022,38（10）：1088-1091.
[15]柳诗意,张宁,孟祥飞,等.补肾活血方通过调节OPG/RANK/RANKL系统对慢性肾脏病大鼠血管钙化的抑制作用[J].中华中医药杂志,2016,31(5):1652-1658.
[16]王莉华,周静威.从“去宛陈莝”论治慢性肾脏病[J].四川中医,2023,41(5):63-65.
[17]邢越洋,王深,张宏旭,等.基于“去宛陈莝”理论探析慢性肾脏病中活血药物的应用[J].中国民族民间医药,2023,32(2):4-6.
[18]周鹏,孙妲男,李勇,等.解毒活血汤对慢性肾脏病大鼠肾脏FGF23、Klotho表达的影响[J].陕西中医,2024,45(1):13-16，22.
[19]申正日,刘鹏,李平.李平教授运用活血化瘀法治疗慢性肾脏病经验[J].中国中西医结合肾病杂志,2023,24(12):1044-1045.
[20]孙红颖,聂莉芳.聂莉芳教授运用活血化瘀法辨治慢性肾脏病的经验研究[J].中国中西医结合肾病杂志,2022,23(9):758-759.
[21]王艳文,李小会,陈丽名,等.活用“去宛陈莝”理论治疗慢性肾衰竭[J].吉林中医药,2022,42(1):28-32.
[22]陈星蕊,汤瑜晨,庄家蝶,等.连翘不同部位化学成分及药理作用研究进展[J].甘肃中医药大学学报,2024,41(6):53-67.
[23]李月阳,雷根平,董盛,等.柴胡的现代药理作用研究进展[J].海南医学院学报,2022,28(22):1748-1754.
[24]杨敏,丁传波,马葭葭.葛根素药理活性研究进展[J].人参研究,2021,33(6):62-64.
[25]牟春燕,殷越,沈子芯.当归化学成分及药理作用研究进展[J].山东中医杂志,2024,43(5):544-551.
[26]吴玲芳,王子墨,赫柯芊,等.赤芍的化学成分和药理作用研究概况[J].中国实验方剂学杂志,2021,27(18):198-206.
[27]张妍妍,韦建华,卢澄生,等.桃仁化学成分、药理作用及质量标志物的预测分析[J].中华中医药学刊,2022,40(1):234-241.
[28]江宝瑞,丁宏,王跃,等.枳壳的药理研究进展[J].云南中医中药杂志,2022,43(6):70-75.
[29]白启荣,郭姣洁,吴娇.红花的化学成分及药理作用研究进展[J].新乡医学院学报,2024,41(1):88-94，100.
[30]齐爽,张飞,王佳贺.甘草抗衰老药理作用及机制的研究进展[J].实用老年医学,2024,38(4):325-329.
[31]杨灡,孙妲男,李勇,等.解毒活血汤对慢性肾脏病大鼠肾脏Smad2、Smad3表达的影响[J].陕西中医,2025,46(1):19-24.
[32]LEASK A,ABRAHAM D J.All in the CCN family:Essential matricellular signaling modulators emerge from the bunker[J].Cell Sci,2006,119(23):4803-4810.
[33]秦曼,吕孝冬,仲维娜.中医药防治肾小管上皮细胞转分化的研究进展[J].黑龙江中医药,2015,44(2):74-75.

相似文献/References:

[1]屈 凯,王悦彤,王漱非,等.基于文献研究探讨益肾散结法防治肾小球硬化的理论内涵*[J].陕西中医,2019,(7):919.
　QU Kai,WANG Yuetong,WANG Shufei,et al.Based on literature research to explore the theoretical connotation of Kidney-reinforcing and Mass-disintegrating for prevention and treatment of glomerulosclerosis[J].,2019,(12):919.
[2]任永朋,华 琼,刘彦妍,等.中医“治未病”思想在防治肾脏病中的应用*[J].陕西中医,2019,(8):1101.
　REN Yongpeng,HUA Qiong,LIU Yanyan,et al.The application of the thought of “preventive treatment of disease” in the prevention and treatment of kidney disease in traditional Chinese medicine[J].,2019,(12):1101.
[3]张宏强,李桂霞,章彩凤,等.许筠治疗慢性肾病临床药对举隅*[J].陕西中医,2020,(6):808.[doi:DOI:10.3969/j.issn.10007369.2020.06.031]
[4]陈紫薇,陈 明△.从脾论治慢性肾脏病的生物学基础探讨*[J].陕西中医,2020,(11):1627.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.029]
　CHEN Ziwei,CHEN Ming..Discuss the biological foundation for chronic disease therapy from treatment through the spleen[J].,2020,(12):1627.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.029]
[5]董 怡,马 静,余楠楠,等.大黄复方保留灌肠辅助治疗慢性肾脏病疗效及对患者生活质量的影响[J].陕西中医,2021,(7):910.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.026]
　DONG Yi,MA Jing,YU Nannan,et al.Effect analysis of rhubarb compound retention enema adjuvant treatment of chronic kidney disease and its impact on patients' quality of life[J].,2021,(12):910.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.026]
[6]齐 宁,宋姝西,刘香玉,等.参芪延肾方治疗慢性肾脏病疗效及对患者半乳糖缺陷IgA1、晚期糖基化终产物和微炎性反应状态的影响[J].陕西中医,2022,(5):596.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.012]
　QI Ning,SONG Shuxi,LIU Xiangyu,et al.Effects of Shenqi Yanshen recipe on the levels of Gd-IgA1,AGEs and micro inflammatory response in patients with chronic kidney disease[J].,2022,(12):596.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.012]
[7]麦芳雄,张香兰,朱德礼.温肾健脾清化汤辅助治疗脾肾气虚型慢性肾脏病疗效及对患者血清转化生长因子β1、纤维连接蛋白水平的影响[J].陕西中医,2022,(8):1068.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.019]
　MAI Fangxiong,ZHANG Xianglan,ZHU Deli.Clinical efficacy of Wenshen Jianpi Qinghua decoction in the treatment of chronic kidney disease with spleen-kidney qi deficiency and its effect on serum transforming growth factor β1 and fibronectin levels[J].,2022,(12):1068.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.019]
[8]杨淑彬,李 婷,李晓妮,等.不同中药结肠透析模式对慢性肾脏病患者胃肠道症状和营养状态的影响[J].陕西中医,2022,(12):1698.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.010]
　YANG Shubin,LI Ting,LI Xiaoni,et al.Effects of different colon dialysis modes of traditional Chinese medicine on gastrointestinal symptoms and nutritional status in patients with chronic kidney disease[J].,2022,(12):1698.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.010]
[9]陈 曦,董凯旋,周 荣,等.中药调控p38丝裂原活化蛋白激酶/核因子κB通路治疗肾纤维化研究进展[J].陕西中医,2023,(7):980.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.036]
　CHEN Xi,DONG Kaixuan,ZHOU Rong,et al.Research progress of traditional Chinese medicine regulating p38MAPK/NF-κB pathway in treatment of renal fibrosis[J].,2023,(12):980.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.036]
[10]周 林,禹 红,刘毓玲,等.活肾通络方联合依那普利对慢性肾脏病患者纤维化标志物、人附睾蛋白4水平的影响[J].陕西中医,2023,(10):1400.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.014]
　ZHOU Lin,YU Hong,LIU Yuling,et al.Effect of Huoshen Tongluo decoction and enalapril on renal function,fibrosis markers and HE4 levels in patients with chronic renal disease[J].,2023,(12):1400.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.014]

备注/Memo

备注/Memo:
黑龙江省自然科学基金资助项目(LH2021H086)；黑龙江省中医药科研项目(ZHY2020-139，ZHY2022-176)；黑龙江省博士后研究人员落户黑龙江科研启动金资助项目(LBH-Q21190)；黑龙江省中医药管理局中医药科研课题 （ZHY2025-042）；黑龙江省中医药管理局青年中医药科研课题（ZHY2025-278）；黑龙江中医药大学校基金资助项目(201115)
更新日期/Last Update: 2025-12-08